🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Cellular Immunotherapy, Adoptive

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy NCT05646576NA1 site📍 Boston Massachusetts General Hospital · Tests: Palliative Care, Usual Care A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab NCT02621021Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: young TIL, Pembrolizumab, Aldesleukin, Fludarabine, Cyclophosphamide A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) NCT06557265Phase 1, Phase 219 sites📍 Little Rock📍 Tustin📍 Gainesville Nkarta, Inc. · Tests: NKX019, Fludarabine, Cyclophosphamide Long-Term Follow up of Patients Undergoing Hematopoietic Stem Cell Transplantation, Cellular Therapy, or Gene Therapy NCT03000244n/a1 site📍 Bethesda National Cancer Institute (NCI) Intraperitoneal SK-NK Cell Injection for Advanced Ovarian Cancer With Massive Ascites NCT07435701Phase 1, Phase 21 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: SK-NK Cell Injection Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC NCT07467863Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Dual-target CAR-NK cells, Lymphodepleting chemotherapy, Supportive Care Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer NCT07551362Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-DT-CAR-NK, Fludarabine, Cyclophosphamide Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma NCT07598955Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Cyclophosphamide, Fludarabine, EB-CAR30-NK, EB-CAR5-NK, EB-CARMSLN-NK T Cell Therapy of Opportunistic Cytomegalovirus Infection NCT02982902EARLY Phase 11 site📍 Cleveland Mari Dallas · Tests: CMV specific adoptive t-cells A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV) NCT04422912Phase 1, Phase 213 sites📍 Redwood City📍 Sacramento📍 New Haven Cabaletta Bio · Tests: DSG3-CAART, CABA-201 Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease NCT07192900Phase 11 site📍 Pittsburgh David Bartlett, MD · Tests: locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2 Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute Leukemia NCT06845592NA1 site📍 Perugia University Of Perugia · Tests: total marrow/lymphoid irradiation Eight-Treg Study:Trial of Adoptive Immunotherapy With Autologous ex Vivo Expanded Regulatory CD8+ T Cells in Living Donor Kidney Transplant Recipients NCT06777719Phase 11 site📍 Nantes Nantes University Hospital · Tests: Eight Treg Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG NCT06221553Phase 11 site📍 Bangkok Chulalongkorn University · Tests: B7H3 specific CAR T cell with IL-7Ra signaling domain Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors NCT07443020Phase 11 site📍 Pittsburgh Allegheny Singer Research Institute (also known as Alleghen… · Tests: locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2 (IL-2) Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors NCT06612645Phase 11 site📍 Bangkok Chulalongkorn University · Tests: B7H3-IL7Ra CAR-T cells Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT) NCT06193759Phase 11 site📍 Washington D.C. Children's National Research Institute · Tests: Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized… Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias NCT06364423Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Autologous HuCD19 ( Anti-CD19)CAR T cells, Cyclophosphamide, Fludarabine, Rituximab N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy NCT07261657EARLY Phase 11 site📍 Chicago Seth Pollack · Tests: Biospecimen Collection, Computed Tomography, Leukapheresis, Magnetic Resonance Imaging, Nogapendekin Alfa Inbakicept A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer NCT05361174Phase 1, Phase 211 sites📍 Los Angeles📍 Miami📍 Orlando Iovance Biotherapeutics, Inc. · Tests: IOV-4001 Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer NCT07462650Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-DUO-CAR-NK-CEA/GCC (IV) E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers NCT05686226Phase 23 sites📍 Bethesda📍 New Brunswick📍 New Brunswick Christian Hinrichs · Tests: E7 TCR-T cells, Aldesleukin R-MVST Cells for Treatment of Viral Infections NCT05183490Phase 11 site📍 New York Columbia University · Tests: Rapidly generated virus specific T (R-MVST) cells Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC NCT07641023Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Dual-target CAR-NK cells, Lymphodepleting chemotherapy, Supportive care Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer NCT07589543Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-DUALNK, Cyclophosphamide, Fludarabine A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma NCT06486051Phase 23 sites📍 Auckland📍 Christchurch📍 Newtown Malaghan Institute of Medical Research · Tests: Fludarabine, Cyclophosphamide, WZTL-002 CAR T-cells Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant NCT04815356Phase 11 site📍 Bethesda National Cancer Institute (NCI) · Tests: CD22CART cell infusion Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma NCT07480928Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1), EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1), Lymphodep… CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies NCT05442515Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: CD19/CD22-CAR-transduced T cells, cyclophosphamide, fludarabine Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) NCT07744256Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-DART-NK01, Lymphodepleting chemotherapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy